Edesa Biotech FY26 Q3 net loss widens to $5.4 million; operating expenses rise to $5.5 million

Reuters2026/08/13 20:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Fiscal Q3 net loss widened to $5.4 million, or $0.60 a share, from a $1.7 million loss, or $0.25 a share.
Operating expenses climbed to $5.5 million from $1.9 million, led by R&D rising to $4 million from $939,067.
Cash and cash equivalents totaled $10.3 million, leaving working capital of $6.9 million at June 30, 2026.
Preparations finished for a Phase 2 EB06 vitiligo study; site activation began post-quarter, with Canada recruitment expected in coming weeks.
Exploratory ARDS analyses in patients with acute kidney injury linked paridiprubart to significant mortality reductions, with MAKE30 endpoint improvements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131615PRIMZONEFULLFEED9809149) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Edesa Biotech FY26 Q3 net loss widens to $5.4 million; operating expenses rise to $5.5 million

You may also like

Crypto prices